KOZLOV et al. Appln. No. 09/839,164 Filed: April 23, 2001 Figure 1 of 20




FIG. 1

KOZLOV et al. Appln. No. 09/839,164 Filed: April 23, 2001 Figure 2 of 20




FIG. 2

KOZLOV et al. Appln. No. 09 839,164 Filed: April 23, 2001 Figure 3 of 20




FIG. 3

KOZLOV et al. Appln. No. 09/839,164 Filed: April 23, 2001 Figure 4 of 20




FIG. 4




FIG. 5




FIG. 6





FIG. 7

KOZLOV et al. Appln. No. 09 839,164 Filed: April 23, 2001 Figure 8 of 20

FIG. 8



Days after the second 5FU injection






FIG. 9




Days of the first week after treatment

FIG. 10A




Days of the third week after treatment

FIG. 10B



Days after transplantation of the bone marrow

FIG. 11



Part of femur transplanted

FIG. 12




FIG. 13






FIG. 14



KOZLOV et al. Appln. No. 09.839,164 Filed: April 23, 2001 Figure 15B of 20



Analysis: Channel A

Peak No.	Time	Type	Height(µY)	Area(μΥ-sec)	Area%
1	4.383	N1	3945	95125	0.119
2	5.080	N2	28639	330889	0.413
3	5.216	N3	49084	531867	0.665
4	7.980	N1	399424	1110511	1.389
5	8.100	Err '	1203320	2882013	3.605
6	8.241	N3	443249	1506159	1.884
7	8.386	N4	481563	2185702	2.734
8	8.533	N5	412886	1826165	2.284
9	8.701	N6	321500	842122	1.053
10	8.745	N7	404661	1610380	2.014
11	8.995	N8	435765	2489721	3.114
12	9.316	N9	517790	4801831	6.007

FIG. 15B

KOZLOV et al. Appln. No. 09/839,164 Filed: April 23, 2001 Figure 15C of 20



FIG. 15C

## FIG. 16A

Lys AAG Lys AAG CTC P.r.o CC 1 117 118 119 A la 17 ACC A la CCC G.13 G.00 Lys AAG C.1, ACC ACC 17r ACC Ash AAC 1 38 Ser 100 His Pre 110 Phe IC Val GTC yy Pro CCC G1y GCC Pro CCC 1.37 1.57 ACC Asn AAC S S S Lys AAG Phe 110 1.8 C.E. S6 Lys AAG Wet ATG Val GIC 6.13 Ser ICC Val GTT A SP GAC Pro Pro CC 1 to 1 CC 1 113 114 ¥ 20 0.00 € 10 G 1n CAG Asp GAC Asp CAC A 18 OCC ار 50 75 Pre 710 S3 Ala CCC Ser AGC Val GTG Val G1C His CAC 111 112 Ala CCC Het ATG Arg CCC Val G1C Ser IC I H1S CAC A la Lys AAG Arg Acg 1 31 Ser IC I C1y CCC CTT Ala OCC A la OCC Val GTC C10 GAC Val C1C Lys AAG SO His CAC 108 100 100 Leu CTG Asn AAC Leu CTG Ser AGC A la OCC His CAC 174 ACC Leu CTG Phe 11C 17 ACC A la OCC Asn AAC Ala CCC Val GTG G1u GAG L ys AAG Lys AAG Asp GAC 1 hr ACC His CAC 105 106 Lev Lev CTG CTG 1 Asp GAC Ala GCG Leu CTG Asp GAC Leu CIG Pre 11C Ala CCC G1y GCT Lee CTG A la CCC CAC His CAC 10k Cys TCC P 130 Ser [CC 177 1A1 Ser AGC Pro CCC Asp GAC His CAC C1u Ser TCT Lea CTC Ala CCC Phe TTC Ala CCC Ser AGC Leu CTG C 1y CCC A la CCC His CAC 177 1AC Val GTG Let A La Ser ICC Val Lys AAG 174 ACC

Arg CC 1

## FIG. 16B

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Val His Lev Thr Pro Glu Glu Lys Ser Ala Val Thr Ala Lev Trp Gly Lys Val Asn Val GIG CAC CIG ACT CCT CAG CAG AAG TCT CCC GIT ACT GCC CTG IGG CCT AAG GIG AAC GTG 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 Gly Glu Ala Leu Gly Arg Leu Leu Val Val Tyr Pro Trp Thr Glu Arg GGT GAG GCC CTG GGC AG GTG CTG GTG TAC CTT TGG ACC CAG AGG 21 22 23 24 Asp Glu Val Gly G GAI GAA GII GGI G

4) 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Phe Phe Clu Ser Phe Gly Asp Leu Ser Thr Pro Asp Ala Val Het Gly Ash Pro Lys Val

62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 90 Ala His GJy Lys Lys Val Leu GJy Ala Phe Ser Asp GJy Leu Ala His Leu Asp Asn OCI CAI GGC AAG AAA GIG CIC GGI GCC 111 AGI GAI GGC CIG GCI CAC CIG GAC AAC 26 Z AAG


106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 Gly Lys GLY ASN Val Leu Val Cys Val Leu Ala His His Phe GCC AAC GIG CIG GIC TGI GIG CIG GCC CAI CAC 111 Ξ CAI CAC כוכ כוכ כוכ וכו כוכ כוכ כככ 104 105 106 1 Arg Lev Lev C Glu Asn C


121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 GLn tys val val Ala Gly val Ala Asm CAG AAA GTG GTG GCT GGT GTG GCT AAT Gln Ala Ala Tyr CAG GCT GCC TAT GIU Phe Thr Pro Pro Val GAA TIC ACC CCA CCA GIC

141 142 143 144 145 146 Leu Ala His Lys Tyr His C1G GCC CAC AAG 1A1 CAC

FIG. 16C

50 50 50 50 50	100 100 100 100 100	150 150 150 150 150	200 200 200 200 200 200
50 WYONEPHT WYONEPHT PHENY SEP WYONESE HANNESE HANNESE WYONEPHEN PHENY SEP	100 NES NEDI TEM TLSI NES NEDI TEMSI SI NES- (MEDI TEMSI SI	150 - KETASUSTA - KAZAGARA - KETASUSTA - KETASUSTA - KETANUSTA - KETANUSTA	200
40 LIST RATUS FE LIST REASE LIST	90 AVAHADDYEN GLAYIDDILKG AVGHIDDILKG AVGHIDDILGG GLAHIDDILGG GLAHIDDILGG	140 FTPAV IASILE FTPAVIASILE FTPAAGAASILE FVPAAGAASILE FVPSVIASILE FVPSVIASILE	190
30 HA-GEYGNER -NVDEVGER HG-AEYGNER EEVGER Q-GAHGNER GEVGSER	80 V.C.A ESE VADALAS V ITAEND VADALAS	130 Vylaniele Cvitatielo Vylaniele Vylaniele Vylaniele Vylaniele	180
20 VKANMGKUĞA VINA NGKV IKANGKIĞĞ VSCL NGKVIS VKANMGKVĞĞ	70 SAQVK BHGKK NITKVKAHGKK SAQVKBHGKK NA KVKAHGGK SDQVKAHGBK NITKVKAHGGK	120 NF KLISH CLI NF KLISH CLI NF KLISH CLI NF KLISH CLI NF KLISH CLI	170
10 V-LSPADKIN VHLIPEBKSA V-LSSEDKSA VHLIDABKAR V-LSPADKAN VHLSPADKAN	09 105   10	110 HAHCGRUDEA EDKCHRUDEA HAHCGRUDEA HAHCGRUDEA HAHCGRUDEA HODEA	160 LISECRA LI
<u></u>	51 51 51 51 51 51	101 101 101 101 101 101	151 151 151 151 151 151
hHema, pep hHemB, pep mHema, pep mHemB, pep pHema, pep	hHema.pep hHemB.pep mHema.pep mHemB.pep pHema.pep	hHemA.pep hHemB.pep mHemA.pep mHemB.pep pHemA.pep	hHemA.pep hHemB.pep mHemA.pep mHemB.pep pHemA.pep





KOZLOV et al. Appln. No. 09/839,164 Filed: April 23, 2001 Figure 18 of 20




FIG. 18

KOZLOV et al. Appln. No. 09/839,164 Filed: April 23, 2001 Figure 19A and 19B of 20



FIG. 19A




FIG. 19B

